Image Source: Unsplash
 

Abbott Laboratories (NYSE: ABT) has released its financial results for the first quarter of 2025, showcasing robust growth in sales and earnings per share (EPS), while reaffirming its full-year guidance. The company’s diversified portfolio continues to drive its performance, even amidst challenging market conditions.
 

Abbott Reports First Quarter Results with $10.36 Billion in Revenue, $1.09 EPS

Abbott Laboratories reported a successful first quarter in 2025, with sales totaling $10.358 billion, reflecting a 4.0% increase compared to the same period last year. On an organic basis, sales grew by 6.9%, or 8.3% when excluding COVID-19 testing-related sales. The company’s adjusted diluted EPS was $1.09, surpassing the market expectation of $1.07. This strong performance was attributed to the growth across various segments, particularly in the Medical Devices and Nutrition divisions.

In the Nutrition segment, Abbott’s sales increased by 3.8% on a reported basis and 6.8% organically. The growth was led by the success of products like Ensure and Glucerna, which cater to specific nutritional needs. Pediatric Nutrition saw a 3.2% increase in global sales, while Adult Nutrition experienced a 4.4% rise.

The Medical Devices segment reported a 9.9% increase in sales on a reported basis and 12.6% organically. This growth was driven by Diabetes Care, Structural Heart, Heart Failure, and Electrophysiology products. Notably, the FreeStyle Libre continuous glucose monitors contributed significantly to the segment’s success, with sales reaching $1.7 billion.
 

Abbott Reaffirms Full-Year 2025 Guidance

Looking ahead, Abbott has reaffirmed its full-year 2025 guidance, projecting organic sales growth between 7.5% and 8.5%. The company anticipates an adjusted operating margin of 23.5% to 24.0% of sales and adjusted diluted EPS ranging from $5.05 to $5.25. For the second quarter of 2025, Abbott expects adjusted diluted EPS to be between $1.23 and $1.27.

Abbott’s strategic initiatives and product innovations continue to support its positive outlook. The company recently obtained a CE Mark for its Volt PFA System, which treats atrial fibrillation, and has commenced its commercial use in the EU. Additionally, Abbott’s U.S. pivotal trial, TECTONIC, aims to evaluate its Coronary Intravascular Lithotripsy System for treating severe calcification in coronary arteries. These advancements, coupled with investments in manufacturing and R&D facilities in Illinois and Texas, are expected to drive future growth.

Abbott’s commitment to shareholder returns is evident through its 405th consecutive quarterly dividend, with a payout of $0.59 per share. The company has consistently increased its dividend for 53 years, underscoring its financial strength and commitment to delivering value to shareholders.

More By This Author:

Bank Earnings Recap: Which One Is Best Positioned For 2025?
Bank of America Reports Strong First Quarter Earnings With $0.90 EPS
Johnson & Johnson Reports Strong Q1 Performance